AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

A grandmother from Fife is undergoing an ambitious personal challenge to walk 60km in six days raising funds for the British ...

If you often feel short of breath when you talk, walk a short distance, or use the stairs, you might think it is just a ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...

On January 5, 2026, under Health and Human Services Secretary Kennedy's leadership, the Centers for Disease Control and Prevention (CDC) released changes to America's longstanding vaccination ...

Patients who have comorbid COPD with heart failure and ischemic heart disease have increased health care resource use and higher mortality.

Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (COPD), casting a shadow over the programme. On the ...

Background The relationship of social determinants of health (SDOH), environmental exposures and medical history to lung function trajectories is underexplored. A better understanding of these ...

Background Exacerbations are major causes of morbidity in individuals with chronic respiratory diseases such as chronic ...

Healio Pulmonology has compiled the top news on COPD posted in 2025.Readers were most interested in how pulmonary ...